Please assess the completion status of the following clinical trial:

Trial Title: Involved-Field Radiation Therapy in Treating Patients With Previously Untreated Stage I or Stage II Low-Grade Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage I or II, low-grade, non-Hodgkin's lymphoma~  * Follicular lymphoma grade I, II, or III~ * Small lymphocytic lymphoma~ * Lymphoplasmacytoid lymphoma~ * Nodal marginal zone lymphoma~* Previously untreated disease~* At least 1 measurable or evaluable mass at least 1.1 cm (except for patients with stage I disease where the entire mass was removed for diagnostic purposes) NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of indolent or aggressive lymphoma will replace the former terminology of low, intermediate, or high grade lymphoma. However, this protocol uses the former terminology.~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* WHO 0-2~Life expectancy:~* Not specified~Hematopoietic:~* WBC greater than 2,000/mm \^3~* Platelet count greater than 100,000/mm\^3~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* No other prior or concurrent malignancy except basal cell skin cancer or carcinoma in situ of the cervix~* No psychological, familial, sociological, or geographical condition that would preclude study participation~* Not pregnant or nursing~* Fertile patients must use effective contraception~* HIV negative~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* No other concurrent anticancer therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).